Precision BioSciences (DTIL) announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene editing treatment for Duchenne muscular dystrophy, DMD, is being evaluated in the Phase 1/2 FUNCTION-DMD study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences announces oral presentation at ASGCT 2026
- Precision BioSciences announces grant of inducement awards
- Precision Bio’s 15-Year HBV Follow-Up Study: What Investors Should Know
- Precision BioSciences assumed with a Buy at JonesResearch
- Precision BioSciences receives CTA approval to expand Eliminate-B trial